Eli Lilly Execs Worry About Effect Of Novo-Catalent Deal On Production Of Lilly Drugs
The Wall Street Journal · 02/06 17:14
Share
Please log in to view news
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
Share your ideas here…
All Comments
Related News
Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs
The Wall Street Journal · 6d ago
Making Money Off the Weight-Loss Revolution Has Even Wall Street Befuddled
The Wall Street Journal · 05/09 12:00
Amgen Knocks Novo Nordisk's Ozempic Stock Rally
The Wall Street Journal · 05/03 14:16
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2024 Webull. All Rights Reserved